Gail Cawkwell's most recent trade in Aclaris Therapeutics Inc was a trade of 15,000 Restricted Stock Units done . Disclosure was reported to the exchange on July 1, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Aclaris Therapeutics Inc | Gail Cawkwell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2023 | 15,000 | 45,000 | - | - | Restricted Stock Units | |
Aclaris Therapeutics Inc | Gail Cawkwell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2023 | 15,000 | 15,000 (0%) | 0% | - | Common Stock | |
Aclaris Therapeutics Inc | Gail Cawkwell | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.37 per share. | 01 Jul 2023 | 5,407 | 9,593 (0%) | 0% | 10.4 | 56,071 | Common Stock |
Aclaris Therapeutics Inc | Gail Cawkwell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 105,000 | 105,000 | - | - | Employee Stock Option (Right to Buy) | |
Aclaris Therapeutics Inc | Gail Cawkwell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 30,000 | 30,000 | - | - | Restricted Stock Units | |
Intercept Pharmaceuticals Inc | Gail Cawkwell | SVP, Med Affairs, Safety & PV | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.80 per share. | 12 Feb 2022 | 320 | 35,740 (0%) | 0% | 15.8 | 5,056 | Common Stock |
Intercept Pharmaceuticals Inc | Gail Cawkwell | SVP, Med Affairs, Safety & PV | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 11,300 | 11,300 | - | - | Option to Purchase Common Stock | |
Intercept Pharmaceuticals Inc | Gail Cawkwell | SVP, Med Affairs, Safety & PV | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 6,600 | 36,060 (0%) | 0% | 0 | Common Stock | |
Intercept Pharmaceuticals Inc | Gail Cawkwell | SVP, Med Affairs, Safety & PV | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.04 per share. | 12 Nov 2021 | 319 | 31,915 (0%) | 0% | 19.0 | 6,074 | Common Stock |
Intercept Pharmaceuticals Inc | Gail Cawkwell | SVP, Med Affairs, Safety & PV | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.28 per share. | 12 Aug 2021 | 319 | 32,234 (0%) | 0% | 15.3 | 4,874 | Common Stock |
Intercept Pharmaceuticals Inc | Gail Cawkwell | SVP, Med Affairs, Safety & PV | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.75 per share. | 12 May 2021 | 319 | 32,553 (0%) | 0% | 17.7 | 5,662 | Common Stock |
Intercept Pharmaceuticals Inc | Gail Cawkwell | SVP, Med Affairs, Safety & PV | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.32 per share. | 12 Feb 2021 | 319 | 32,872 (0%) | 0% | 31.3 | 9,991 | Common Stock |
Intercept Pharmaceuticals Inc | Gail Cawkwell | SVP, Med Affairs, Safety & PV | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2021 | 19,700 | 19,700 | - | - | Option to Purchase Common Stock | |
Intercept Pharmaceuticals Inc | Gail Cawkwell | SVP, Med Affairs, Safety & PV | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2021 | 12,600 | 33,191 (0%) | 0% | 0 | Common Stock | |
Intercept Pharmaceuticals Inc | Gail Cawkwell | SVP, Med Affairs, Safety & PV | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.52 per share. | 12 Nov 2020 | 319 | 21,297 (0%) | 0% | 38.5 | 12,288 | Common Stock |
Intercept Pharmaceuticals Inc | Gail Cawkwell | SVP, Med Affairs, Safety & PV | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.44 per share. | 12 Aug 2020 | 319 | 21,616 (0%) | 0% | 53.4 | 17,047 | Common Stock |